Taylor M - Search Results

1

An integrated reactive metabolite evaluation approach to assess and reduce safety risk during drug discovery and development.

Reese M, Sakatis M, Ambroso J, Harrell A, Yang E, Chen L, Taylor M, Baines I, Zhu L, Ayrton A, Clarke S. Reese M, et al. Among authors: taylor m. Chem Biol Interact. 2011 Jun 30;192(1-2):60-4. doi: 10.1016/j.cbi.2010.10.005. Epub 2010 Oct 21. Chem Biol Interact. 2011. PMID: 20970409

2

Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.

Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE. Sakatis MZ, et al. Among authors: taylor ma. Chem Res Toxicol. 2012 Oct 15;25(10):2067-82. doi: 10.1021/tx300075j. Epub 2012 Sep 19. Chem Res Toxicol. 2012. PMID: 22931300

3

Evaluation of a Three-Dimensional Primary Human Hepatocyte Spheroid Model: Adoption and Industrialization for the Enhanced Detection of Drug-Induced Liver Injury.

Schofield CA, Walker TM, Taylor MA, Patel M, Vlachou DF, Macina JM, Vidgeon-Hart MP, Williams A, McGill PJ, Newman CF, Sakatis MZ. Schofield CA, et al. Among authors: taylor ma. Chem Res Toxicol. 2021 Dec 20;34(12):2485-2499. doi: 10.1021/acs.chemrestox.1c00227. Epub 2021 Nov 19. Chem Res Toxicol. 2021. PMID: 34797640

4

Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations.

Patel A, Wilson R, Harrell AW, Taskar KS, Taylor M, Tracey H, Riddell K, Georgiou A, Cahn AP, Marotti M, Hessel EM. Patel A, et al. Among authors: taylor m. Drug Metab Dispos. 2020 Apr;48(4):307-316. doi: 10.1124/dmd.119.089003. Epub 2020 Feb 2. Drug Metab Dispos. 2020. PMID: 32009006 Clinical Trial.

5

Navigating CYP1A Induction and Arylhydrocarbon Receptor Agonism in Drug Discovery. A Case History with S1P1 Agonists.

Taylor SJ, Demont EH, Gray J, Deeks N, Patel A, Nguyen D, Taylor M, Hood S, Watson RJ, Bit RA, McClure F, Ashall H, Witherington J. Taylor SJ, et al. Among authors: taylor m. J Med Chem. 2015 Oct 22;58(20):8236-56. doi: 10.1021/acs.jmedchem.5b01102. Epub 2015 Oct 1. J Med Chem. 2015. PMID: 26393276

6

Disposition and metabolism of darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in humans.

Dave M, Nash M, Young GC, Ellens H, Magee MH, Roberts AD, Taylor MA, Greenhill RW, Boyle GW. Dave M, et al. Among authors: taylor ma. Drug Metab Dispos. 2014 Mar;42(3):415-30. doi: 10.1124/dmd.113.054486. Epub 2013 Dec 30. Drug Metab Dispos. 2014. PMID: 24378325 Clinical Trial.

7

Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects.

Green JA, Mohamed K, Goyal N, Bouhired S, Hussaini A, Jones SW, Koh GC, Kostov I, Taylor M, Wolstenholm A, Duparc S. Green JA, et al. Among authors: taylor m. Antimicrob Agents Chemother. 2016 Nov 21;60(12):7321-7332. doi: 10.1128/AAC.01588-16. Print 2016 Dec. Antimicrob Agents Chemother. 2016. PMID: 27697758 Free PMC article. Clinical Trial.

8

Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.

St Jean PL, Xue Z, Carter N, Koh GC, Duparc S, Taylor M, Beaumont C, Llanos-Cuentas A, Rueangweerayut R, Krudsood S, Green JA, Rubio JP. St Jean PL, et al. Among authors: taylor m. Malar J. 2016 Feb 18;15:97. doi: 10.1186/s12936-016-1145-5. Malar J. 2016. PMID: 26888075 Free PMC article. Clinical Trial.

9

A pharmacometrics approach to assess the feasibility of capillary microsampling to replace venous sampling in clinical studies: Tafenoquine case study.

Bachhav SS, Taylor M, Martin A, Green JA, Duparc S, Rolfe K, Sharma H, Tan LK, Goyal N. Bachhav SS, et al. Among authors: taylor m. Br J Clin Pharmacol. 2023 Mar;89(3):1187-1197. doi: 10.1111/bcp.15554. Epub 2022 Nov 9. Br J Clin Pharmacol. 2023. PMID: 36199201 Free article.

10

Application of the Stable Isotope Label Approach in Clinical Development-Supporting Dissolution Specifications for a Commercial Tablet Product with Tafenoquine, a Long Half-life Compound.

Goyal N, Mohamed K, Rolfe K, Sahota S, Ernest T, Duparc S, Taylor M, Casillas L, Koh GCKW. Goyal N, et al. Among authors: taylor m. AAPS J. 2018 Jun 4;20(4):74. doi: 10.1208/s12248-018-0234-5. AAPS J. 2018. PMID: 29869298 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10,097 results

Search Page

Filters